Mounjaro®
Starting from £179.99/mo
Start journey Learn moreCombining a ketogenic diet with Wegovy is a question that comes up often, and the honest answer is that the clinical trial data for semaglutide 2.4mg was gathered alongside a standardised reduced-calorie diet, not a ketogenic one — so direct evidence for this specific pairing is limited. What the trials do show is that Wegovy's results are meaningful on their own: in the STEP 1 trial, published in the New England Journal of Medicine, participants lost an average of around 15% of their body weight over 68 weeks. Adding a very low-carbohydrate approach on top may appeal to some people, but the interaction deserves a careful look before you commit to both at once. These are prescription-only medicines, and the diet you follow alongside them is part of the clinical picture your prescriber reviews.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial randomised 1,961 adults with obesity or overweight and at least one weight-related condition to either semaglutide 2.4mg weekly or placebo, both groups following a 500 kcal deficit diet with increased physical activity. Average weight loss with semaglutide reached around 15% of body weight at 68 weeks. That figure is robust and reproducible. What it does not tell us is whether a ketogenic version of that diet would have produced a larger number, a smaller one, or simply more side effects.
The reason that matters: GLP-1 medicines like Wegovy work partly by slowing gastric emptying and reducing appetite signals. A ketogenic diet does something structurally similar, ketone bodies suppress ghrelin, the hunger hormone. On paper, pairing them sounds logical. In practice, the degree of appetite suppression can become difficult to manage, and eating too little protein while relying heavily on fat for fuel carries its own risks when you are already losing weight quickly. You can read more about how long Wegovy takes to work and why the early weeks matter for building sustainable habits alongside any diet approach.
The NHS advises following a reduced-calorie diet during treatment, without specifying a macronutrient split. That is deliberate: rigid dietary rules are harder to sustain, and Wegovy's efficacy does not depend on carbohydrate restriction.
There are plausible reasons why some people find the combination useful. Both approaches reduce overall food intake. A ketogenic diet stabilises blood glucose, which may ease some of the energy dips people notice in the first weeks of Wegovy. And for people who have used keto before, the familiar food framework gives structure at a time when appetite signals are changing rapidly.
The friction points are less discussed but worth knowing. Wegovy commonly causes nausea, constipation and fatigue, effects that are most pronounced early in treatment and after each dose increase. A strict ketogenic diet in its first fortnight often produces the same trio, sometimes called the 'keto flu'. Starting both simultaneously means two adjustment periods running concurrently with no clean way to identify which is causing what. Our clinical team's profile at Mostafa Damghani gives a sense of the kind of prescriber-level thinking that goes into questions like this, it is not a decision made by algorithm.
Constipation deserves a specific mention. Wegovy slows gastric motility. A ketogenic diet is often lower in fibre. The combination is a fairly reliable recipe for bowel discomfort, and patients who experience severe or persistent stomach pain should seek medical attention promptly given the MHRA's updated guidance on gastrointestinal effects and acute pancreatitis with GLP-1 medicines. Report any unexpected reactions via the Yellow Card scheme.
The dietary factor with the clearest evidence base on GLP-1 treatment is not carbohydrate restriction, it is protein adequacy. When appetite is significantly suppressed, total food intake drops, and if protein drops with it, the body preferentially loses lean muscle mass alongside fat. Preserving muscle matters both for metabolic health and for sustaining weight loss once treatment eventually ends.
Ketogenic diets can be high in protein, but they do not have to be. A standard keto template that is predominantly fat-heavy and only moderate in protein could leave someone on Wegovy in a genuine deficit. The practical suggestion from dietitians working in this space is to prioritise protein at every meal before carbohydrate decisions, and to keep an eye on total intake rather than assuming appetite suppression handles everything. Tracking intake for a few weeks at the start of treatment gives useful data regardless of which diet approach you choose.
For a broader picture of what results look like across the treatment journey, early Wegovy results at two weeks and beyond are documented separately, with realistic framing about what to expect at each stage. One note on routine that prescribers often raise: storing your pen correctly (refrigerated, typically in the fridge door where temperature is stable) affects whether the medicine works as it should, check the Patient Information Leaflet for your exact storage window.
No published randomised trial has directly compared Wegovy plus a ketogenic diet against Wegovy plus a standard calorie-reduced diet in a head-to-head design. Reviews on this combination pull from observational data, case series and extrapolation from the GLP-1 mechanism, useful background, not definitive evidence. That gap is likely to close as the research matures, but for now any claim that keto specifically amplifies Wegovy's results beyond the STEP 1 figures should be treated as speculative. People curious about what progress typically looks like can explore Wegovy results before and after treatment, which sets out realistic expectations grounded in the available evidence.
NICE's appraisal of semaglutide (TA875) recommends it as part of a specialist weight management programme, and the dietary component of that programme is designed around individual circumstances rather than a single template. If you are weighing up whether a specific dietary approach makes sense alongside treatment, that is exactly the kind of question a prescriber or registered dietitian should help you answer, not one to resolve based on forum threads. Those who want to understand what happens right at the start of treatment may find it helpful to read about Wegovy 1 week results, covering what is and is not realistic to notice in those very first days. You can find an overview of licensed treatment options at our weight-loss treatment page, and if cost is part of your planning, Wegovy pricing information is set out plainly with no hidden fees. If you have questions before starting, our FAQs cover many of the things people want to know.
If you would like a prescriber to review your situation and discuss what dietary approach makes sense for you, check your eligibility with our clinical team.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.